{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:20:27Z","timestamp":1760242827429,"version":"build-2065373602"},"reference-count":24,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>This Special Issue, entitled \u201cMolecules against Alzheimer\u201d, gathers a number of original articles, short communications, and review articles on recent research efforts toward the development of novel drug candidates, diagnostic agents and therapeutic approaches for Alzheimer\u2019s disease (AD), the most prevalent neurodegenerative disorder and a leading cause of death worldwide. This Special Issue contains many interesting examples describing the design, synthesis, and pharmacological profiling of novel compounds that hit one or several key biological targets, such as cholinesterases, \u03b2-amyloid formation or aggregation, monoamine oxidase B, oxidative stress, biometal dyshomeostasis, mitochondrial dysfunction, serotonin and\/or melatonin systems, the Wnt\/\u03b2-catenin pathway, sigma receptors, nicotinamide phosphoribosyltransferase, or nuclear erythroid 2-related factor. The development of novel AD diagnostic agents based on tau protein imaging and the use of lithium or intranasal insulin for the prevention or the symptomatic treatment of AD is also covered in some articles of the Special Issue.<\/jats:p>","DOI":"10.3390\/molecules21121736","type":"journal-article","created":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T10:55:28Z","timestamp":1481885728000},"page":"1736","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Special Issue: \u201cMolecules against Alzheimer\u201d"],"prefix":"10.3390","volume":"21","author":[{"given":"Michael","family":"Decker","sequence":"first","affiliation":[{"name":"Pharmazeutische und Medizinische Chemie, Institut f\u00fcr Pharmazie und Lebensmittelchemie, Julius-Maximilians-Universit\u00e4t W\u00fcrzburg, Am Hubland, 97074 W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-8555","authenticated-orcid":false,"given":"Diego","family":"Mu\u00f1oz-Torrero","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII, 27-31, E-08028 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,12,16]]},"reference":[{"key":"ref_1","unstructured":"Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., and Prina, M. (2015). World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost & Trends, Alzheimer\u2019s Disease International. Available online: http:\/\/www.alz.co.uk."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40266-015-0273-x","article-title":"The use of cholinesterase inhibitors across all stages of Alzheimer\u2019s disease","volume":"32","author":"Deardorff","year":"2015","journal-title":"Drugs Aging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer\u2019s disease: An appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Int. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/cmdc.201500041","article-title":"New approaches in the design and development of cannabinoid receptor ligands: Multifunctional and bivalent compounds","volume":"10","author":"Nimczick","year":"2015","journal-title":"ChemMedChem"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.2174\/0929867322666150812145825","article-title":"From bitopic inhibitors to multitarget drugs for the future treatment of Alzheimer\u2019s disease","volume":"22","author":"Perez","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/0929867321666141106122628","article-title":"Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer\u2019s disease","volume":"22","author":"Guzior","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Pisani, L., Farina, R., Soto-Otero, R., Denora, N., Mangiatordi, G.F., Nicolotti, O., Mendez-Alvarez, E., Altomare, C.D., Catto, M., and Carotti, A. (2016). Searching for multi-targeting neurotherapeutics against Alzheimer\u2019s: Discovery of potent AChE-MAO B inhibitors through the decoration of the 2H-chromen-2-one structural motif. Molecules, 21.","DOI":"10.3390\/molecules21030362"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Boulebd, H., Ismaili, L., Bartolini, M., Bouraiou, A., Andrisano, V., Martin, H., Bonet, A., Moraleda, I., Iriepa, I., and Chioua, M. (2016). Imidazopyranotacrines as non-hepatotoxic, selective acetylcholinesterase inhibitors, and antioxidant agents for Alzheimer\u2019s disease therapy. Molecules, 21.","DOI":"10.3390\/molecules21040400"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Hebda, M., Bajda, M., Wi\u0119ckowska, A., Sza\u0142aj, N., Pasieka, A., Panek, D., Gody\u0144, J., Wichur, T., Knez, D., Gobec, S., and Malawska, B. (2016). Synthesis, molecular modelling and biological evaluation of novel heterodimeric, multiple ligands targeting cholinesterases and amyloid beta. Molecules, 21.","DOI":"10.3390\/molecules21040410"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Saathoff, J.M., Liu, K., Chojnacki, J.E., He, L., Chen, Q., Lesnefsky, E.J., and Zhang, S. (2016). Mechanistic insight of bivalent compound 21MO as potential neuroprotectant for Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21040412"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jones, M., Wang, J., Harmon, S., Kling, B., Heilmann, J., and Gilmer, J.F. (2016). Novel selective butyrylcholinesterase inhibitors incorporating antioxidant functionalities as potential bimodal therapeutics for Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21040440"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dgachi, Y., Bautista-Aguilera, O.M., Benchekroun, M., Martin, H., Bonet, A., Knez, D., Gody\u0144, J., Malawska, B., Gobec, S., and Chioua, M. (2016). Synthesis and biological evaluation of benzochromenopyrimidinones as cholinesterase inhibitors and potent antioxidant, non-hepatotoxic agents for Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21050634"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rampa, A., Tarozzi, A., Mancini, F., Pruccoli, L., di Martino, R.M.C., Gobbi, S., Bisi, A., de Simone, A., Palomba, F., Zaccheroni, N., and Belluti, F. (2016). Naturally inspired molecules as multifunctional agents for Alzheimer\u2019s disease treatment. Molecules, 21.","DOI":"10.3390\/molecules21050643"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Prati, F., Cavalli, A., and Bolognesi, M.L. (2016). Navigating the chemical space of multitarget-directed ligands: From hybrids to fragments in Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21040466"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Herrera-Arozamena, C., Mart\u00ed-Mar\u00ed, O., Estrada, M., de la Fuente Revenga, M., and Rodr\u00edguez-Franco, M.I. (2016). Recent advances in neurogenic small molecules as innovative treatments for neurodegenerative diseases. Molecules, 21.","DOI":"10.3390\/molecules21091165"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Li, Z., Mu, C., Wang, B., and Jin, J. (2016). Graveoline analogs exhibiting selective acetylcholinesterase inhibitory activity as potential lead compounds for the treatment of Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21020132"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mantoani, S.P., Chierrito, T.P.C., Vilela, A.F.L., Cardoso, C.L., Mart\u00ednez, A., and Carvalho, I. (2016). Novel triazole-quinoline derivatives as selective dual binding site acetylcholinesterase inhibitors. Molecules, 21.","DOI":"10.3390\/molecules21020193"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kr\u00e1tk\u00fd, M., \u0160t\u0115p\u00e1nkov\u00e1, S., Vor\u010d\u00e1kov\u00e1, K., \u0160varcov\u00e1, M., and Vin\u0161ov\u00e1, J. (2016). Novel cholinesterase inhibitors based on O-aromatic N,N-disubstituted carbamates and thiocarbamates. Molecules, 21.","DOI":"10.3390\/molecules21020191"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Chen, Y., Yang, X., Chen, T., Ji, J., Lan, L., Hu, R., and Ji, H. (2016). Treatment with Akebia saponin D ameliorates A\u03b21-42-induced memory impairment and neurotoxicity in rats. Molecules, 21.","DOI":"10.3390\/molecules21030323"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kong, Y., Guan, Y., Hua, F., Zhang, Z., Lu, X., Zhu, T., Zhao, B., Zhu, J., Li, C., and Chen, J. (2016). Optimization and biodistribution of [11C]-TKF, an analog of tau protein imaging agent [18F]-THK523. Molecules, 21.","DOI":"10.3390\/molecules21081019"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"De-Paula, V.D.J., Kerr, D.S., Fabiano de Carvalho, M.P., Schaeffer, E.L., Talib, L.L., Gattaz, W.F., and Forlenza, O.V. (2015). Long-term lithium treatment increases cPLA2 and iPLA2 activity in cultured cortical and hippocampal neurons. Molecules, 20.","DOI":"10.3390\/molecules201119663"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ribari\u010d, S. (2016). The rationale for insulin therapy in Alzheimer\u2019s disease. Molecules, 21.","DOI":"10.3390\/molecules21060689"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/12\/1736\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:28:46Z","timestamp":1760210926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/21\/12\/1736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,16]]},"references-count":24,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["molecules21121736"],"URL":"https:\/\/doi.org\/10.3390\/molecules21121736","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2016,12,16]]}}}